🇺🇸

US SEC Filing Intelligence

· daily

Dow Jones 30 Stocks SEC Filings — May 27, 2026

The 50 filings for the Dow 30 stream reveal a bifurcated earnings landscape: while technology leaders like Salesforce and Marvell deliver record revenue and surging AI-driven growth, consumer-facing names like Bath & Body Works and U-Haul show clear signs of demand softening and margin compression. A dominant theme is the aggressive pivot toward AI and data infrastructure, with Salesforce's Agentforce ARR surging over 200% YoY and Marvell raising its outlook on AI demand, even as capital allocation shifts heavily toward buybacks and debt financing. Several filings highlight significant insider activity and governance changes, including a notable retraction of a credit facility announcement from Fold Holdings and a major $3.5B take-private acquisition of Veris Residential. Period-over-period comparisons reveal a mixed picture: revenue growth is present but often comes at the cost of compressed margins (e.g., Home Depot's sales up 4.8% but operating income down 3.0%), while capital markets activity remains robust with large debt issuances from Oncor and Molson Coors. The overall sentiment is cautiously optimistic, with clear winners in AI and infrastructure, but growing risks in consumer discretionary and real estate segments.

21 high priority 29 medium 50 total filings
· daily

US SEC Filings Daily Market Digest — May 27, 2026

The May 27, 2026 filings reveal a bifurcated market: large-cap retailers like Home Depot and Dick's Sporting Goods show revenue growth but margin compression, while small-cap companies like GridAI and Trillion Energy face severe financial distress. Notable M&A activity includes Worthington Steel's clearance for Klöckner acquisition and GameStop's non-binding bid for eBay. Biotech Apogee Therapeutics reported strong Phase 2 data and secured $1.3B non-dilutive financing, while Precision BioSciences showed promising HBV data with safety concerns. Insider activity is limited, but capital allocation trends show dividend increases at Movado and G-III Apparel, while many small caps rely on ATM offerings. The overall theme is selective strength in established companies versus cash-burning small caps.

20 high priority 30 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — May 27, 2026

The 50 filings from the S&P 500 Consumer Discretionary sector reveal a sector bifurcating between winners and laggards. Home Depot posted revenue growth (+4.8% YoY) but operating income fell 3%, while Abercrombie & Fitch recorded record Q1 sales but saw both comparable sales and margins decline. In contrast, Marvell Technology and Salesforce delivered standout results with 28% and 13% YoY revenue growth respectively, driven by AI adoption, but both face deceleration risks. Insider and capital allocation signals are sparse but notable: BuzzFeed's majority sale to Byron Allen at $3/share, Fold Holdings retracting a credit facility claim, and Willis Lease Finance failing a supermajority vote on a stock split all signal stress in smaller names. A significant cluster of late-filed 13Fs from Kentucky Farm Bureau Mutual Insurance (reporting 2016-2018 holdings) suggests no current portfolio relevance. Several SPAC and micro-cap governance filings add noise. The most actionable themes are: AI-driven growth in tech-discretionary names (Marvell, Salesforce), real estate and credit fund liquidity events (First Realty NJ sale for $28.8M, Oaktree/StepStone/BlackRock private credit steady NAVs), and financial distress signals in Pacific Oak REIT (default lawsuit) and Borealis Foods (delisting risk). Overall, the sector shows low single-digit core growth with margin pressure, but AI and specialty finance offer alpha generation opportunities.

11 high priority 39 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — May 27, 2026

The 39 filings from the S&P 500 Healthcare sector reveal a sector bifurcated between established players showing operational discipline and early-stage entities facing existential capital and legal challenges. Period-over-period data shows strong revenue growth at **nCino** (10.6% YoY) and **Citi Trends** (14.4% YoY), with the latter more than doubling its Adjusted EBITDA, while **Pacira BioSciences** highlights record revenues ($726.4M) and a successful proxy defense. However, significant risk is concentrated in **Pacific Oak Strategic Opportunity REIT** (facing an $80M default lawsuit), **Artelo Biosciences** (FINRA arbitration claim), and **Minerva Neurosciences** (dilutive $75M ATM offering). A major sector-defining event is the overwhelming shareholder approval (98.9% for) of **Webster Financial's** acquisition by Banco Santander, despite significant dissent on executive compensation. The most actionable forward-looking catalyst is **NewHold Investment Corp. III's** $2.4B merger with Newcleo, a nuclear technology firm with a $220M oversubscribed PIPE, offering a unique, albeit high-risk, exposure to next-gen energy. Overall, the sector shows a clear pattern of capital flowing towards de-risked, cash-flow-positive businesses while speculative, pre-revenue entities face a more challenging funding environment.

17 high priority 22 medium 39 total filings
· daily

US Executive Compensation Proxy SEC Filings — May 27, 2026

This batch of 12 proxy filings reveals a landscape dominated by corporate actions that carry significant shareholder implications, ranging from redomiciliation and dilutive capital raises to SPAC business combinations and governance shifts. A key theme is the prevalence of 'mixed' sentiment filings (Gates Industrial, Nukkleus, Translational Development), where management proposes actions that offer strategic benefits but simultaneously introduce risks like dilution or reduced shareholder protections. Period-over-period comparisons are largely absent from the provided enriched data, limiting trend analysis, but forward-looking statements and transaction details are rich with actionable intelligence. The most critical developments are the high-risk SPAC deal for Live Oak Acquisition Corp. V (no fairness opinion, no redemption threshold) and the dilutive capital raises at Nukkleus and Caring Brands, which demand immediate investor attention. Insider trading activity is not explicitly detailed in the enriched data, but management conviction can be inferred from board recommendations and the structure of proposed transactions. The portfolio-level pattern is one of capital-seeking entities (SPACs, small-cap biotechs) using shareholder votes to secure survival or growth, while more established firms (Gates Industrial, Capital Southwest) focus on governance optimization and routine matters.

12 high priority 12 total filings
· daily

US IPO Pipeline SEC S-1 Filings — May 27, 2026

The IPO pipeline is dominated by three distinct capital-raising events and one transformative exchange offer, signaling a bifurcated market where distressed companies seek emergency funding while growth platforms execute strategic acquisitions. LiqTech International's S-1 reveals acute cash needs, with $1.1M in high-discount notes issued just two months before the offering, while urban-gro's S-1 marks a radical pivot from a discontinued agriculture business to a cricket media platform, creating valuation uncertainty. SoundHound AI's S-4 for LivePerson acquisition introduces a collar mechanism that caps stock consideration, reflecting market volatility concerns, while HBT Financial's exchange offer is a routine debt management move. Period-over-period data from the enriched filings shows no direct revenue or margin trends across the set, but insider activity is notably absent, and forward-looking guidance is limited to deal timelines. The most critical development is urban-gro's complete business transformation, which carries a materiality score of 10/10 and demands immediate investor attention.

4 high priority 4 total filings
· daily

Global High-Priority Regulatory Events — May 27, 2026

This digest synthesizes 50 high-priority filings from May 27, 2026, revealing a market dominated by financial distress signals and major strategic pivots. A significant cluster of insolvency and regulatory non-compliance filings (Ansal Properties, Impex Ferro Tech, Unitech International, Quadrant Televentures, Shree Hanuman Sugar) underscores severe stress in Indian industrial and real estate sectors, with multiple companies in CIRP and facing fines for board composition failures. Conversely, high-stakes M&A activity is reshaping the energy and technology landscapes, with NextEra's proposed acquisition of Dominion Energy and GameStop's audacious bid for eBay signaling a potential wave of transformative deals. Period-over-period data reveals a stark divergence: while Home Depot and Gandhar Oil Refinery show resilient revenue growth (4.8% and 8.8% YoY respectively), deep value destruction is evident at Trillion Energy (revenue down 58.9% YoY, net loss widening to $49.2M) and Hi-Great Group (revenue down 46.6% YoY, cash nearly depleted). The most critical development is the confluence of a major SPAC merger (ProLogium at $3.8B valuation) and a massive biotech financing (Apogee's $1.3B deal with Blackstone), highlighting a market that is simultaneously funding innovation while punishing weak balance sheets. Portfolio-level patterns indicate a 'flight to quality' with capital flowing to companies with clear catalysts and strong insider conviction, while companies with governance lapses or deteriorating fundamentals face rapid de-rating.

50 high priority 50 total filings
· daily

US Earnings Financial Results SEC Filings — May 27, 2026

The 41 filings reveal a bifurcated earnings season. While top-line growth is present across several sectors (Home Depot +4.8%, Box +10.7%, AMSC +34.3%, Synopsys +41.9%), margin compression and rising costs are a dominant theme, with 5 of 16 new filings showing operating income declines despite revenue growth. The most acute distress is concentrated in micro-cap companies like Hi-Great Group (revenue -46.6%, cash near zero) and Nature's Miracle (revenue -96%), while larger firms like Modine and U-Haul face operational headwinds from depreciation and restructuring charges. Insider activity is notably absent from the enriched data, but capital allocation patterns show aggressive buybacks at Box ($115M in quarter) and Synopsys ($262.5M), contrasted with dividend increases at StepStone (+37% YoY). The 25 CarMax trust filings are procedural and carry no actionable intelligence. The most compelling opportunities lie in AMSC's 34% revenue growth with a swing to profitability, Semtech's 37% net income growth, and nCino's operational leverage (swung from -$1.5M to +$21.1M operating income).

41 high priority 41 total filings
· daily

US SEC Trading Suspension Halt Orders — May 27, 2026

The five filings for May 27, 2026, reveal a severe cluster of Nasdaq non-compliance events, with all five companies receiving deficiency notices for late filings, low market values, or insufficient equity. This concentration of regulatory risk suggests a broader market trend of small-cap distress, likely driven by tight financing conditions and operational challenges. Period-over-period comparisons are not directly available for these specific filings, but the recurrence of late filings (Borealis, Greenwave) and the failure to regain compliance after initial notices (Liminatus, SOBR Safe) indicate deteriorating financial controls and liquidity. The most critical development is the potential delisting of Liminatus Pharma, which has exhausted its compliance period and is now in a high-stakes appeal. The market implications are significant: investors face heightened delisting risk, potential trading halts, and severe share price volatility across these names. The portfolio-level pattern is a clear 'delisting wave' in the micro-cap space, with no bullish signals and a uniform negative sentiment across all filings.

5 high priority 5 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — May 27, 2026

The 50 filings from May 27, 2026, paint a stark picture of a bifurcated market: a wave of distressed micro-caps is aggressively seeking emergency capital through dilutive ATMs, convertible notes, and private placements, while larger, more stable companies are opportunistically refinancing debt and pursuing strategic M&A. The most critical theme is the surge in Nasdaq non-compliance and going-concern risks, with at least five companies (Borealis Foods, Greenwave Technology, Liminatus Pharma, SOBR Safe, Callan JMB) facing potential delisting. This distress is concentrated in the small-cap biotech and technology sectors, where cash burn and failed trials are forcing existential restructuring. In contrast, the energy and digital infrastructure space is seeing significant capital deployment, highlighted by DigitalBridge's $1.05B acquisition of ArcLight and newcleo's $2.4B SPAC merger. Insider activity is notably absent from these filings, but capital allocation patterns—aggressive dilution vs. strategic debt refinancing—clearly separate the survivors from the distressed. The period-over-period data from BDCs (Golub Capital, PennantPark) shows flat-to-declining net asset values, signaling a cautious outlook for credit markets. The most actionable intelligence lies in the distressed names where the structure of rescue financing (e.g., HWH International's control-diluting deal) creates both extreme risk and potential for asymmetric returns.

50 high priority 50 total filings
· daily

US Executive Officer Management Changes SEC — May 27, 2026

The 32 filings reveal a dynamic period for US executive and director changes, marked by significant leadership transitions at key companies like Bath & Body Works, Immunic, and Braze, alongside routine governance updates. A notable trend is the high frequency of CFO changes, with six filings (Bath & Body Works, Arq, Rollins, Braze, Six Flags, and Zurn Elkay) involving CFO appointments or departures, signaling potential strategic pivots or operational challenges. Period-over-period comparisons show a mixed financial landscape: Agilent and Braze reported strong revenue growth (10% and 30.2% YoY, respectively), while Bath & Body Works saw a 3% sales decline and margin compression. Insider activity was limited, but significant shareholder dissent was observed at Honest Company and Xerox, indicating governance concerns. Forward-looking statements from Immunic (pivotal Phase 3 data) and Braze (continued acceleration) offer catalysts, while guidance reaffirmation at Bath & Body Works and raised guidance at Agilent provide contrasting outlooks. Overall, the filings suggest a market in transition with both opportunities and risks concentrated in specific sectors like biotech and consumer goods.

32 high priority 32 total filings
· daily

US Corporate Board Director Changes SEC Filings — May 27, 2026

The 32 filings from May 27, 2026, reveal a bifurcated market where strong operational performance at Agilent and Braze contrasts with consumer-facing weakness at Bath & Body Works. Board room changes are dominated by routine governance (annual meetings, equity plan approvals) and leadership transitions, with notable CEO appointments at Immunic (pre-commercial biotech) and Kemper (insurance turnaround). A key theme is the high level of shareholder dissent on equity dilution, with Xerox (25.5% against) and Dermata (low 'For' votes) flagging governance risk. Insider activity is limited, but the CFO departures at Bath & Body Works and Rollins introduce transition risk. Period-over-period data shows a mixed picture: Agilent's 10% revenue growth and margin expansion contrast with Bath & Body Works' 3% sales decline and 280 bps gross margin compression. The most critical developments are the high-stakes catalyst at Immunic (Phase 3 data readout) and the significant management overhaul at Braze, which accompanies strong revenue growth but margin pressure.

32 high priority 32 total filings
· daily

US Merger & Acquisition SEC Filings — May 27, 2026

The US M&A landscape on May 27, 2026, reveals a market bifurcated between high-conviction, high-value transactions and distressed SPACs facing existential regulatory and financial pressures. The most significant development is the $3.8 billion de-SPAC merger between ProLogium and TDAC, a high-risk/high-reward play in next-gen battery technology, while the completed $3.5 billion take-private of Veris Residential demonstrates strong private equity appetite for real assets. However, a troubling pattern emerges among SPACs: three entities (Charlton Aria, ASPAC III, Flag Ship) have received Nasdaq deficiency notices for late filings or low equity, signaling systemic operational and compliance failures. The Live Oak-Teamshares deal introduces significant governance risk by proceeding without a fairness opinion or redemption threshold. Capital markets remain open for new SPAC IPOs, with Oceanhawk and Amanat raising a combined $235 million, indicating continued sponsor appetite despite the sector's headwinds. The overall sentiment is mixed, with a clear divergence between well-capitalized, execution-focused deals and a cohort of struggling blank-check companies.

10 high priority 10 total filings
· monthly

US Pre-Market SEC Filings Roundup — May 27, 2026

The overnight filing cycle reveals a market bifurcated between robust operational execution in select industrials and consumer discretionary names versus acute financial distress in micro-cap and pre-revenue companies. Dycom Industries and Dick's Sporting Goods posted standout revenue growth of 56% and 63% YoY respectively, driven by acquisitions and organic share gains, though margin compression from deal costs is a clear headwind. Conversely, Trillion Energy, Hi-Great Group, and GridAI Technologies reported widening losses and deteriorating cash positions, signaling severe liquidity risks. The healthcare sector is a key source of alpha, with Apogee Therapeutics announcing positive Phase 2 data and a $1.3B non-dilutive financing deal, while Immunic appointed a new CEO ahead of a pivotal Phase 3 readout. Capital allocation patterns are mixed: Movado raised its dividend by 14%, while Callan JMB and Data Storage Corp authorized dilutive ATM offerings. A major M&A theme is emerging with GameStop's non-binding $125/share bid for eBay and the ProLogium SPAC merger at a $3.8B valuation, both carrying significant execution risk. Insider activity is sparse in this batch, but the high number of restatements (Goldenwell Biotech) and going-concern warnings (NextTrip) demand caution. Overall, the data suggests a 'barbell' market where strong operators are rewarded and weak balance sheets are punished, with healthcare catalysts and M&A providing the most actionable near-term opportunities.

20 high priority 30 medium 50 total filings
· daily

Biotech Small-Cap Approvals — May 26, 2026

During the single-day period of May 26, 2026, the FDA issued 7 approvals, all classified as 'Other' (generic/biosimilar entries). There were zero NMEs, zero biosimilars (in the traditional biologic sense), and zero label expansions, resulting in a low-catalyst session for biotech investors. The dominant theme is generic erosion of established branded franchises, with notable entries for EMPAGLIFLOZIN (Aurobindo, targeting Jardiance) and SITAGLIPTIN/METFORMIN (Mankind Pharma, targeting Janumet). The only bullish signal came from Galderma’s label expansion for ADAPALENE/BENZOYL PEROXIDE (DIFFERIN/EPIDUO franchise), though materiality is moderate. Key risk: the wave of small-molecule generics approved here increases IRA exposure risk for originators, as these drugs face Medicare price negotiation at year 9 post-approval.

7 total filings
· daily

Big Pharma Approvals — May 26, 2026

The May 26, 2026 approval stream is exceptionally narrow, comprising a single label expansion for AbbVie’s linaclotide (LINZESS). There were no NME, biosimilar, or other label expansion approvals during this period, resulting in no dominant therapeutic area theme. The highest-conviction signal is the bullish label expansion for linaclotide, which extends AbbVie’s GI franchise but carries only moderate commercial materiality given the drug’s established market presence. The key watch item is the lack of NME or biosimilar approvals, which provides no fresh pipeline or competitive disruption signals for the sector.

1 total filings
· daily

New Drug Approvals (Original) — May 26, 2026

This digest covers 7 FDA approvals from May 20-22, 2026, all classified as 'Other' (non-NME, non-biosimilar, non-label-expansion) with a mix of one label expansion and six generic/biosimilar-type approvals. The dominant theme is generic/biosimilar competition across established therapeutic categories—dermatology, CNS, diabetes, and thyroid—with no novel molecular entities or breakthrough designations. The highest-conviction signal is the label expansion for ADAPALENE, BENZOYL PEROXIDE (DIFFERIN EPIDUO ACNE GEL) by GALDERMA LABORATORIES, L.P, which is bullish for Galderma's dermatology franchise. A key risk is the lack of NME approvals, signaling a quiet period for innovative pipeline catalysts, while the cluster of generic approvals for high-volume drugs like SITAGLIPTIN, METFORMIN HYDROCHLORIDE and EMPAGLIFLOZIN may pressure originator revenues for Merck and Boehringer Ingelheim/Eli Lilly, respectively.

7 total filings
· daily

S&P 500 Technology Sector SEC Filings — May 26, 2026

The 9 filings in this S&P 500 Technology stream reveal a bifurcated landscape: while routine corporate governance events (annual meetings, auditor ratifications) at smaller financial firms like NorthEast Community Bancorp and First Northern Community Bancorp show stable shareholder support, the most material and actionable intelligence centers on a major strategic pivot at Cogent Communications and a deep financial restructuring at Veradigm. Cogent's $225M sale of 10 data centers to I Squared Capital signals a clear shift toward a pure-play optical IP network model, a high-materiality event (7/10) that could unlock value but lacks disclosed financial impact. Veradigm's long-awaited 10-K filings expose a severe deterioration: revenue declined 5.1% YoY to $594M, net income swung from +$49M to -$292M, and adjusted EBITDA fell 28.5% to $94M, with preliminary 2025 guidance suggesting a further 1-2% decline. The Genco Shipping & Trading proxy fight with Diana Shipping adds a high-stakes M&A catalyst (materiality 9/10), where Genco argues Diana's $23.50 offer is inadequate but acknowledges its stock has only traded above that level 40% of the time in 2026, creating a binary event. Across the stream, period-over-period comparisons highlight margin compression and revenue declines at Veradigm, while Cogent's divestiture and Genco's defense provide contrasting opportunities. Insider activity is notably absent from these filings, but forward-looking data (Veradigm's guidance, Cogent's closing date, Genco's tender timeline) builds a catalyst calendar for the next 30-60 days.

3 high priority 6 medium 9 total filings
· daily

Nasdaq 100 Stocks SEC Filings — May 26, 2026

The May 26, 2026 filing batch reveals a market bifurcated between aggressive corporate action and operational distress. The most material themes are a hostile takeover battle in dry bulk shipping (Genco vs. Diana), a major SPAC merger in quantum computing (Axiom/Terra Quantum), and a significant financial reporting crisis at Veradigm, which finally filed long-delayed 10-Ks showing a sharp 5.1% revenue decline and a swing to a $292M net loss. Period-over-period data highlights a clear trend of margin compression and revenue deceleration in the healthcare IT and shipping sectors. Capital allocation is mixed, with Genco defending its dividend against a low-ball bid, while NIQ Global receives strong shareholder backing for a buyback authorization. Insider activity is notably absent in most filings, but the Veradigm consulting agreement signals a desperate need for financial controls. The overarching theme is that while some companies are pursuing transformative M&A (Axiom, Cogent), others are fighting for survival or facing significant governance headwinds, creating a high-dispersion environment for active investors.

7 high priority 9 medium 16 total filings
· daily

S&P 500 Financials Sector SEC Filings — May 26, 2026

The 50 filings for S&P 500 Financials on May 26, 2026 reveal a sector bifurcated between capital-rich institutions deploying leverage and smaller entities facing existential liquidity pressures. Key period-over-period trends include margin compression across industrials and specialty finance, with CSW Industrials experiencing a 490 bps operating margin decline despite 23% revenue growth, while Ares Capital and Ares Strategic Income Fund secured $9.6 billion in combined credit facilities, signaling robust institutional access to capital. The most critical developments include GameStop's unsolicited $125/share bid for eBay, Cumberland Pharmaceuticals' $100M asset sale to Apotex, and Northern Oil & Gas's $259M entry into Canadian Duvernay Shale, all representing transformative M&A. Portfolio-level patterns show a clear divergence: large-cap financials and BDCs are expanding leverage and returning capital via buybacks and dividends, while micro-cap firms like TransCode Therapeutics and Nuvve Holding face Nasdaq delisting risks due to equity deficiencies and filing failures.

19 high priority 31 medium 50 total filings